Skip to main content

Together we are beating cancer

Donate now

Search Results: "PARP inhibitor"

Showing 12 out of 122 results

We spoke to Professor Andrew Tutt about how you build a successful scientific team, the importance of translation and why you always need a touch of humbleness… We spoke to Professor Andrew Tutt about how you build a successful scientific team, the importance of translation and why you always need a touch of humbleness…

by Phil Prime | Interview | 10 April 2022

10 April 2022

The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research. The episode features Steve Jackson. Steve is the University of Cambridge Frederick James Quick Professor of Biology. He is also Head of Cancer Research UK Laboratories at the Wellcome Trust/Cancer Research UK Gurdon Institute. He talks about the difference between academic and commercial science, tips for forming a spinout company and what we should aim for in the next 20 years of cancer research.

by Phil Prime | Podcast | 23 March 2022

23 March 2022

This entry is part 2 of 9 in the series Cancer Research Matters - series 1
A photograph of a lab at the Imperial Cancer Research Fund in the 1960's.
  • Science & Technology
  • Health & Medicine

Diving into our role in 50 top cancer drugs

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today. To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities' that led to many of the drugs in use today.

by Catherine Pickworth | In depth | 9 February 2022

9 February 2022

The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life. The first episode features Ruth Plummer. Ruth is Professor of Experimental Cancer Medicine at Newcastle University and Director of the CRUK Newcastle Cancer Centre. She talks about how the DNA repair inhibition field has changed over 20 years, her instrumental role in the development of the PARP inhibitor Rucaparib and why work/life balance is so important for the future of research life.

by Phil Prime | Podcast | 4 February 2022

4 February 2022

This entry is part 1 of 9 in the series Cancer Research Matters - series 1

Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach. Chief scientist Karen Vousden, contemplates the advances coming from cell biology and genomics and why the new frontiers of cancer research require a systems biology approach.

by Cancer Research UK | Analysis | 4 February 2022

4 February 2022

Computational analysis of cancer

From a legacy of life-saving medicines to developing new tools to detect cancer, our scientists have been at the forefront of cancer research for 120 years. From a legacy of life-saving medicines to developing new tools to detect cancer, our scientists have been at the forefront of cancer research for 120 years.

by Katie Roberts | Analysis | 2 February 2022

2 February 2022

Breast cancer screening

Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding. Cancer Research UK-funded scientists are using innovative techniques to understand how resistance to a targeted cancer drug is unfolding.

by Lilly Matson | Analysis | 10 January 2022

10 January 2022

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials - we tell the story from discovery to translation. Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials - we tell the story from discovery to translation.

by Cancer Research UK | In depth | 5 November 2021

5 November 2021

Human breast cancer cells.

Around 10,600 fewer breast cancer patients have started treatment in the last year in England, as experts fear hard-won progress could slow. Around 10,600 fewer breast cancer patients have started treatment in the last year in England, as experts fear hard-won progress could slow.

by Cancer Research UK | News | 15 June 2021

15 June 2021

Lung adenocarcinoma cells
  • Science & Technology
  • Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

by Harry Jenkins | Analysis | 9 June 2021

9 June 2021